ABL Biotechnologies Peer Comparison

BSE: 526955

₹0.81

₹0.02 (3.05%)

As on 11-Jul-2016IST

Market cap

₹1 Cr

Revenue (TTM)

₹-- Cr

P/E Ratio

--

P/B Ratio

0

Div. Yield

0 %

Edit

	ABL Biotechnologies	Dishman Carbogen	Lyka Labs	Take Solutions	Bharat Immuno
Market cap (₹ Cr)	1	2,672	302	238	61
Revenue (₹ Cr)	--	2,901	138	85	45
Net Profit (₹ Cr)	-0.13	16.16	-9.39	12.82	-16.64
Net Margin (%)	--	0.55	-6.66	6.38	-36.43
RoE (%)	--	0.29	-9.20	20.84	--
Price to Earnings	--	165.37	--	18.54	--
Price-To-Book	0.05	0.40	3.19	7.41	--

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	ABL Biotechnologies	Dishman Carbogen	Lyka Labs	Take Solutions	Bharat Immuno
Operating Revenue	0.04	0.00	--	703.66	46.34
Total Income	0.01	0.22	--	718.81	47.28
Total Expenditure	0.12	0.00	--	558.57	40.77
EBITDA	-0.12	0.00	--	145.09	5.57
Depreciation	0.07	--	--	26.67	1.24
EBIT	-0.18	0.00	--	118.42	4.33
Interest	0.00	0.18	--	18.28	0.41
Other Income	0.01	0.22	--	15.15	0.94
Exceptional Items	--	--	--	--	1.10
Profit before Tax	-0.18	0.03	--	115.29	5.96
Provision for Tax	--	0.01	--	21.13	-6.60
Profit after Tax	-0.18	0.02	--	94.16	12.56

Liabilities (₹ Cr)

	ABL Biotechnologies	Dishman Carbogen	Lyka Labs	Take Solutions	Bharat Immuno
Shareholder's Funds	18.56	0.05	--	341.95	28.35
Minority Interest	0.00	--	--	37.62	--
Non-Current Liabilities	12.79	8.77	--	143.22	-4.70
Current Liabilities	13.89	0.02	--	217.77	50.28
Total Liabilities	45.24	8.83	--	740.55	80.53

Assets (₹ Cr)

	ABL Biotechnologies	Dishman Carbogen	Lyka Labs	Take Solutions	Bharat Immuno
Non-Current Assets	36.10	0.00	--	346.21	9.38
Current Assets	8.81	8.83	--	394.34	64.54
Total Assets	45.24	8.83	--	740.55	80.53
Total Debt*	17.10	8.77	--	192.73	6.86
Net Current Assets	-5.08	8.82	--	176.57	14.26
Contingent Liabilities	--	--	--	6.38	7.80

Cashflow (₹ Cr)

	ABL Biotechnologies	Dishman Carbogen	Lyka Labs	Take Solutions	Bharat Immuno
Cash From Operating Activities	--	-8.96	--	115.47	4.97
Cash Flow from Investing Activities	--	0.22	--	-81.41	-0.04
Cash from Financing Activities	--	8.77	--	-21.48	-2.79
Net Cash Inflow / Outflow	--	0.03	--	12.58	2.14

Ratios

Profitability Ratios

	ABL Biotechnologies	Dishman Carbogen	Lyka Labs	Take Solutions	Bharat Immuno
ROCE (%)	-0.56	4.88	--	27.40	24.91
ROE (%)	-1.24	61.57	--	31.58	56.73
ROA (%)	-0.40	0.50	--	14.18	24.05
EBIT Margin (%)	-1,256.77	--	--	22.77	14.03
Net Margin (%)	-2,757.31	10.19	--	13.10	26.57
Cash Profit Margin (%)	-1,258.51	--	--	17.17	29.74

Growth Ratios

	ABL Biotechnologies	Dishman Carbogen	Lyka Labs	Take Solutions	Bharat Immuno
Revenue Growth (%)	-100.00	--	--	40.65	1,716.12
EBIT Growth (%)	79.18	--	--	46.52	334.30
Net Profit Growth (%)	70.07	0.00	--	28.02	400.61
EPS Growth (%)	70.06	0.00	--	22.27	400.62
Book Value Growth (%)	-0.89	88.96	--	34.30	77.78

Valuation Ratios

	ABL Biotechnologies	Dishman Carbogen	Lyka Labs	Take Solutions	Bharat Immuno
Price / Earnings	0.00	0.00	--	4.75	2.81
Price / Book Value	0.28	0.00	--	1.19	1.25
Dividend Yield (%)	0.00	--	--	2.95	0.00
EV/EBITDA	-191.01	40.74	--	3.37	3.90
Market Cap (₹ Cr)	7.25	--	--	406.80	35.32

Solvency Ratios

	ABL Biotechnologies	Dishman Carbogen	Lyka Labs	Take Solutions	Bharat Immuno
Debt to Equity	1.18	186.25	--	0.56	0.24
Short term debt to equity ratio	0.23	--	--	0.11	0.24
Current Ratio	0.63	456.03	--	1.81	1.28
Quick Ratio	0.63	456.03	--	1.73	0.89
Interest Coverage	-114.14	1.18	--	7.31	15.44

Operating Efficiency Ratios

	ABL Biotechnologies	Dishman Carbogen	Lyka Labs	Take Solutions	Bharat Immuno
Debtors to sales (%)	752.28	--	--	22.57	57.34
Asset Turnover	0.00	0.00	--	1.06	0.89
Receivable days	2,745.81	--	--	68.12	108.73
Inventory Days	0.00	--	--	7.79	83.68
Payable days	0.00	--	--	78.73	100.09
Cash Conversion Cycle	2,745.81	--	--	-16.50	92.32

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.